BRIDGE Oncology™
Collaborative Care in Advanced NMSC: Connecting Community Dermatologists and the Oncology Teams
Neoadjuvant Cemiplimab For Stage II to IV Cutaneous Squamous-Cell Carcinoma
Gross ND, et al. N Engl J Med. 2022;387(17):1557–1568.
Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study
Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer
Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
Stratigos AJ, Sekulic A, Peris K, et al. J Am Acad Dermatol. 2024;90(2):414-418.
Patient Resources
NCCN Guidelines for Patients: Basal Cell Skin Cancer
NCCN Guidelines for Patients: Squamous Cell Skin Cancer
National Organizations:
AIM at Skin Cancer
AIM at Skin Cancer provides skin cancer education to patients, caregivers, and families with easy-to-understand information on prevention and early detection, treatment, side effects, and survivorship.
Skin Cancer Foundation
Washington, DC Area Resources
George Washington Cancer Center Cutaneous Oncology Program
Inova Life with Cancer
Inova Life with Cancer provides free support to anyone affected by cancer, including nurse navigation, classes, counseling, and support groups across DC, MD, and VA.
Nueva Vida
Nueva Vida offers bilingual cancer navigation and support to the underserved Latino community in the Washington, DC metropolitan area.
Clinical Guidelines and Resources
NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer
NCCN®. 2026.
NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer
NCCN®. 2026.
NCCN Clinical Practice Guidelines in Oncology: Management of Immune Checkpoint Inhibitor-Related Toxicities
riSCC
riSCC is a clinician-focused mobile and web app designed for precise risk stratification of cutaneous squamous cell carcinoma (CSCC) in clinical settings.
BRIDGE ONCOLOGY™
Collaborative Care in Advanced NMSC: Connecting Community Dermatologists and the Oncology Teams
| Faculty: | Jessica Kalen, MD, FAAD; Vishal Anil Patel, MD |
| Release: | 08/06/2026 |
| Expiration: | 09/06/2026 |
